Applied UV, Inc. Stock Price, News & Analysis

Applied UV (NASDAQ:AUVI) has secured orders over $850,000 for its Airocide® air purification systems from 3Sixty Biopharmaceuticals, a leading distributor in Africa. This order is part of a $3.5 million minimum purchase commitment for the first year. The Airocide® technology, originally developed by NASA, effectively eliminates airborne pathogens and is FDA Class II listed. CEO Q Saeed expressed confidence in 3Sixty's capability to enhance Airocide®'s market presence across Africa.

Applied UV, Inc. (NASDAQ: AUVI) announced that independent lab tests confirmed its SteriLumen Lumicide™ Ribbon effectively kills SARS-CoV-2, the virus causing COVID-19. Conducted by CUBRC, Inc., the study showed over 99.9% viral inactivation on stainless steel and ceramic surfaces within 5 to 20 minutes of exposure. These results bolster confidence in SteriLumen's technology for infection control in high-traffic areas such as healthcare and hospitality settings. CEO Q Saeed emphasized the antimicrobial efficacy of the product, further validating its role in combating pathogens.

Applied UV, Inc. (AUVI) announced an exclusive distribution agreement with Viet My Instrument and Technology Joint Stock Company for Airocide® air purification systems in Vietnam. The distributor commits to purchasing at least 100 consumer and 45 commercial systems in the first year. As Vietnam's healthcare spending is projected to grow significantly, Applied UV aims to expand its presence in this high-growth market. The Airocide® technology is known for its effectiveness in eliminating airborne pathogens and has applications in various sectors such as healthcare and hospitality.

Applied UV, Inc. (AUVI) announced the installation of 50 Airocide® Systems at the MUNDUS VINI 2021 wine competition, enhancing air quality for over 300 international wine experts. This initiative demonstrates the growing demand for advanced air purification technologies, particularly in the wine industry. Airocide®, developed with NASA's assistance, effectively eliminates airborne pathogens and is recognized as an FDA Class II Medical device. CEO Q Saeed emphasized the importance of safety measures in re-opening live events amid Covid-19 challenges.

Applied UV has successfully installed 60 Airocide® units in Colegio Santa Elena, Uruguay, as part of its international expansion strategy. This installation follows a $3.5 million first-year purchase commitment from a South African distributor. The Airocide® technology, designed for pathogen elimination, enhances air quality in school settings, helping to combat the effects of remote learning and supporting a return to full attendance. The project is positioned as a prototype for broader implementation across South American schools.

Applied UV (NASDAQ:AUVI) has signed an exclusive distribution agreement with 3Sixty Biopharmaceuticals for the Airocide® air purification systems in Africa. 3Sixty commits to a minimum purchase of $3.5 million in the first year. The partnership aims to enhance air and surface infection control, crucial amid pandemic challenges. The Airocide® technology, originally developed by NASA, is clinically proven to eliminate airborne pathogens and is FDA Class II certified. This agreement sets the stage for potential future product expansions.

Applied UV, Inc. (NASDAQ:AUVI) announced a significant revenue increase of 157.1% in Q1 2021, reaching $2.31 million, driven by the acquisition of Akida Holdings. Despite this growth, the company reported a net loss of $1.03 million, attributed to higher SG&A costs. The firm also emphasized its strategic investments in new technologies and innovation, asserting a strong market position with broad adoption of its Airocide® system across industries. Liquidity remained solid, with a cash balance of $8.9 million as of March 31, 2021.

Applied UV (NASDAQ:AUVI) will host an investor conference call and live webcast on May 17, 2021, at 8:30 am EDT to discuss its Q1 2021 financial results. The results will be accessible through the Investor Relations section of their website. Interested participants can join via a link on Applied UV's site or by dialing +1-888-506-0062 for domestic callers. A replay will be available for a week post-call. Applied UV is a leader in infection control technology, emphasizing UVC solutions for various sectors.

Applied UV, Inc. (AUVI) announced the grant of a patent for its pathogen-destroying device by the Chinese Patent Office, adding to its growing intellectual property portfolio. This marks the tenth patent secured for their UVC-based disinfection technology, which aims to combat the global challenge of infection control. The company currently holds eight patents in the U.S., one in the EU, and one in China, with additional applications pending in various countries. The CEO emphasized the importance of patents in maintaining a competitive advantage and addressing healthcare-acquired infections.